| Grant ID | RP240120 |
| Awarded On | February 21, 2024 |
| Title | JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC |
| Program | Academic Research |
| Award Mechanism | Individual Investigator |
| Institution/Organization | The University of Texas Southwestern Medical Center |
| Principal Investigator/Program Director | Qing Zhang |
| Cancer Sites | Kidney and Renal Pelvis |
| Contracted Amount |
$1,049,997* *Pending contract negotiation |
| Lay Summary |
Estimated new cases and deaths from renal (renal cell and renal pelvis) cancer in the U.S. in 2020 were 73,750 and 14,830 respectively. In kidney cancer, most of patients would lose the function of one critical gatekeeper, so called VHL. Once patients lose VHL, they will likely develop one major type of kidney cancer, so called "clear cell renal cell carcinoma (ccRCC)". Our research found that one particular pathway JMJD6-DGAT1 that may contribute to ccRCC tumor formation. We found that if we get rid of JMJD6 or DGAT1, we can slow down kidney cancer cell growth. More importantly, we also found one specific and potent DGAT1 inhibitor that can be used to slow ccRCC tumor growth and eliminate m... |